Drugs Made In America Acquisition (NASDAQ:DMAA – Get Free Report) released its earnings results on Monday. The company reported $0.05 EPS for the quarter, FiscalAI reports.
Drugs Made In America Acquisition Price Performance
Shares of DMAA stock opened at $10.90 on Tuesday. Drugs Made In America Acquisition has a one year low of $10.32 and a one year high of $10.91. The company’s 50-day simple moving average is $10.87 and its 200-day simple moving average is $10.66.
Institutional Trading of Drugs Made In America Acquisition
A hedge fund recently bought a new stake in Drugs Made In America Acquisition stock. First Trust Capital Management L.P. acquired a new stake in shares of Drugs Made In America Acquisition Corp. (NASDAQ:DMAA – Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 786,459 shares of the company’s stock, valued at approximately $8,557,000. First Trust Capital Management L.P. owned approximately 3.24% of Drugs Made In America Acquisition as of its most recent SEC filing.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings restated a “sell (d)” rating on shares of Drugs Made In America Acquisition in a research note on Wednesday, August 26th. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the stock presently has an average rating of “Sell”.
View Our Latest Stock Report on DMAA
About Drugs Made In America Acquisition
Drugs Made In America Acquisition Corp. is a special purpose acquisition company formed to pursue a merger, asset acquisition, or similar business combination. It does not operate a pharmaceutical business or manufacture drugs itself. The company’s stated focus was on identifying a business in the pharmaceutical industry, particularly one connected with drug manufacturing in the United States. Its activities were centered on seeking a suitable acquisition or merger candidate.
Read More
- Five stocks we like better than Drugs Made In America Acquisition
- Tyson Foods’ 10% Surge Puts a Breakout in Sight, But Wall Street Remains Cautious
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
Receive News & Ratings for Drugs Made In America Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Drugs Made In America Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
